Company Overview and News

1000
Tracking Dan Loeb's Third Point Portfolio - Q1 2018 Update

2018-05-22 seekingalpha
Dan Loeb's 13F portfolio value decreased from $13.86B to $13.32B this quarter. The number of positions decreased from 44 to 40.
PCG ATHTF STZ.B TWX CVS CRM SHW GGAL HON AABA AVGO DOW DOV MELI MAC AET MMM PBF GD TPRE WP KDMN UTX STZ BKI TWC BABA DVMT GOOGL MSFT APY MHK QCOM GRBK MGM FB DOV.WI LEN NXPI PAM PE NFLX PF GOOG BAX LEN.B MPC PAGS ADBE SPGI RSPP VMC MON ICE SWN HON EA WYNN LYB FTI.WI FMC ANTM DWDP BID NEXA BLK XRAY T SUPV DHR ANTX

13
Third Point Reinsurance's (TPRE) CEO Rob Bredahl on Q1 2018 Results - Earnings Call Transcript

2018-05-13 seekingalpha
Greetings, and welcome to the Third Point Reinsurance First Quarter 2018 Earnings Conference Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.
MS.PRI TPRE MS.PRK MS.PRE MS.PRF MS.PRG MS MS.PRA

1
Third Point's Dan Loeb to increase bets against the stock market

2018-05-13 cnbc
Following a quarter in which his two flagship funds posted losses, the head of Third Point said he is increasing short positions that proved to be profitable during an otherwise rough first quarter.
TPRE

0
TPRE / Third Point Reinsurance Ltd. 8-K (Current Report)

2018-05-11 sec.gov
Document UNITED STATES
TPRE

0
TPRE / Third Point Reinsurance Ltd. 10-Q (Quarterly Report)

2018-05-10 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON
TPRE

0
Loeb's Third Point Boosts Short Wagers on Market Disruption - Bloomberg

2018-05-10 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
TPRE

0
TPRE / Third Point Reinsurance Ltd. 8-K (Current Report)

2018-05-09 sec.gov
Document UNITED STATES
TPRE

3
Check These 2 Insurance Stocks Poised for Q1 Earnings Beat

2018-05-04 zacks
The first-quarter earnings season has crossed its midpoint with more than 68% of the S&P 500 index members having reported quarterly results. Per the Earnings Outlook, the beat ratio is impressive with 78.4% of the participants surpassing bottom-line estimates and 75.8%, exceeding the top-line mark. Per the Earnings Outlook, earnings growth is estimated to be in double-digit in 13 of the 16 Zacks sectors including the Finance.
NGHCP NGHCO NGHCN TPRE NGHC NGHCZ

20
Is a Beat in Store for Willis Towers (WLTW) in Q1 Earnings?

2018-05-04 zacks
Willis Towers Watson Public Limited Company (WLTW - Free Report) is slated to report first-quarter 2018 results on May 7, before the market opens. Last reported quarter, the company beat the Zacks Consensus Estimate by 4.74%. Let’s see, how things are shaping up for this announcement. Commissions and fees in the first quarter are likely to have improved on organic growth across all segments and a solid contribution from acquisitions.
NGHCP NGHCO NGHCN TPRE CACU ARW CACI WLTW NGHC NGHCZ

13
Workiva's (WK) CEO Matt Rizai on Q1 2018 Results - Earnings Call Transcript

2018-05-03 seekingalpha
Good afternoon. My name is Rob, and I'll be your conference operator today. At this time, I would like to welcome everyone to the Workiva First Quarter 2018 Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. [Operator Instructions].
MS.PRI TPRE MS.PRK MS.PRE EMCI WK MS.PRF MS.PRG MS MS.PRA SAM

0
TPRE / Third Point Reinsurance Ltd. / BlackRock Inc. - null (Passive Investment)

2018-04-06 sec.gov
bmg8827u1009_040518.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 1) THIRD POINT REINSURANCE LTD -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) BCZNFT1 -------------------------------------------------------- (SEDOL Number) March 31, 2018 -------------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this c
TPRE

0
TPRE / Third Point Reinsurance Ltd. / BlackRock Inc. - null (Passive Investment)

2018-04-06 sec.gov
bmg8827u1009_040518.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 1) THIRD POINT REINSURANCE LTD -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) BCZNFT1 -------------------------------------------------------- (SEDOL Number) March 31, 2018 -------------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this c
TPRE

27
Priceline-parent Booking Holdings stock initiated with buy rating at Mizuho

2018-03-21 marketwatch
Shares of Booking Holdings Inc. are up 0.4% in Wednesday morning trading after analysts at Cowen and Co. raised their 12-month price target on the stock to $2,650, the highest among estimates tracked by FactSet. The analysts, led by Kevin Kopelman, previous had a price target of $2,300 for Booking, which changed its name from Priceline Group last month. Over the next 24 months, the analysts see the potential for Booking's stock to reach $3,000.
EXPE BKNG TPRE ARH.PRC PCLN LB ARHPF FL GSUM ACGL

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

3h - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

CUSIP: G8827U100